Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09OQV
|
|||
| Former ID |
DCL000889
|
|||
| Drug Name |
N-0923
|
|||
| Synonyms |
ent-Rotigotine; 92206-54-7; N-0437; 6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; 112835-48-0; 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-; 2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin; PubChem16422; AC1Q7ALS; rotigotine transdermal patch; AC1L1N7C; SCHEMBL50425; CHEMBL104383; CTK8E7910
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Approved | [1], [2] | |
| Company |
National Cancer Institute (NCI)
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H25NOS
|
|||
| Canonical SMILES |
CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
|
|||
| InChI |
1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3
|
|||
| InChIKey |
KFQYTPMOWPVWEJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 92206-54-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12014593, 14752454, 14752455, 17186146, 43116758, 47207429, 50065448, 50113269, 57313947, 80319505, 92720050, 93308798, 103403788, 104016053, 104317509, 126620376, 126649059, 126652305, 126668282, 128375597, 131331909, 134222775, 134339011, 134339342, 134339911, 134340448, 135016328, 135650929, 137239502, 142666076, 143493345, 144206180, 152240256, 152258902, 160647749, 162011478, 163122815, 170465204, 171578547, 174531819, 175268915, 179151436, 185974303, 187072933, 196106681, 198987592, 204360677, 206711592, 218903400, 223382851
|
|||
| SuperDrug ATC ID |
N04BC09
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. | |||
| REF 2 | Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. Drugs Today (Barc). 2006 Jan;42(1):21-8. | |||
| REF 3 | Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.